MedPath

Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease

Not Applicable
Not yet recruiting
Conditions
Alcoholic Liver Disease
Interventions
Registration Number
NCT03503708
Lead Sponsor
Composite Interceptive Med Science
Brief Summary

Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients. Livitol-17 consist of the 3 whole herbs and extract which has antioxidant, hepatoprotective as well as reno-protective properties. The aim of this trial is to study the efficacy of herbal supplement to improve the liver function of alcoholic liver disease subject.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria

Adults aged over 18 years with the evidence of alcoholic liver disease (ALD) based on a thorough history, physical examination, and laboratory tests and all of the following:

  • Chronic alcohol intake, Identified with AUDIT(Alcohol Use Disorder Inventory Test) Questionnaire
  • Active alcohol use until 4 weeks prior to presentation
  • ALT and AST elevated >1.5 times the upper limit of normal
  • Over 1.5 ratio of AST to ALT
  • Maddrey Discriminant function(DF) less than 30
Exclusion Criteria
  • Severe alcoholic hepatitis with cirrhosis or life expectancy less than 3 months
  • Severe renal impairment (Glomerular filtration rate below 60 ml/min per 1.73m2)
  • Hepatic disorders due to cardiac causes, inherited metabolic causes, hemochromatosis and Wilson's disease
  • Participants with active viral hepatitis
  • Under going active treatment for alcohol withdrawal syndrome(AWS) at the study entry
  • Participants on hepatotoxic medications like antitubercular medication, antiviral medication, paracetamol etc.
  • Pregnant, attempting to conceive, or lactating women
  • Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Intervention GroupLivitol-70All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
Primary Outcome Measures
NameTimeMethod
Change from baseline in ALT(Alanine Aminotransferase)3 months

The above mentioned test will be measured with panel of Liver function test at central laboratory.

Change from baseline in AST(Aspartate Aminotransferase)3 months

The above mentioned test will be measured with panel of Liver function test at central laboratory.

Change from baseline in ALP(Alkaline Phosphatase)3 months

The above mentioned test will be measured with panel of Liver function test at central laboratory.

Number of Subject with adverse events3 months

Adverse events is defined as any untoward medical occurrence that may not necessarily have a causal relationship with the treatment, but resulted in a dose reduction or discontinuation of treatment.

Change from baseline in GGT(Gamma Glutamyl Transferase)3 months

The above mentioned test will be measured with panel of Liver function test at central laboratory.

Change from baseline in serum total bilirubin3 months

The above mentioned test will be measured with panel of Liver function test at central laboratory.

Secondary Outcome Measures
NameTimeMethod
Change in radiological response3 months

The degree of fatty infiltration will be assessed by ultrasound.

Change in maddrey discriminant function(DF)3 months

Trial Locations

Locations (1)

Mazumdar Shaw Medical Centre

🇮🇳

Bangalore, Karnataka, India

© Copyright 2025. All Rights Reserved by MedPath